Skip to main content

Table 4 Treatment-emergent adverse events occurring in ≥10% of patients (safety population, N = 30)

From: Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

TEAE, n (%) Grade 1 Grade 2 Grade 3 Grade 4 Any grade
Hypertension   11 (36.7%) 15 (50%)   26 (86.7%)
Palmar-plantar erthrodysesthesia syndrome 10 (33.3%) 9 (30%) 3 (10%)   22 (73.3%)
White blood cell decreased 12 (40%) 7 (23.3%) 2 (6.7%)   21 (70%)
Neutrophil count decreased 7 (23.3%) 5 (16.7%) 8 (26.7%)   20 (66.7%)
Vomiting 11 (36.7%) 2 (6.7%) 2 (6.7%)   15 (50%)
Decreased appetite 11 (36.7%) 4 (13.3%)    15 (50%)
Nausea 11 (36.7%) 2 (6.7%)    13 (43.3%)
Malaise 11 (36.7%) 1 (3.3%)    12 (40%)
Platelet count decreased 7 (23.3%) 2 (6.7%) 1 (3.3%) 2 (6.7%) 12 (40%)
Diarrhea 4 (13.3%) 2 (6.7%) 4 (13.3%)   10 (33.3%)
Peripheral neurotoxicity 8 (26.7%) 1 (3.3%) 1 (3.3%)   10 (33.3%)
Alanine aminotransferase increased 5 (16.7%) 3 (10%) 1 (3.3%)   9 (30.0%)
Aspartate aminotransferase increased 4 (13.3%) 2 (6.7%) 3 (10.0%)   9 (30.0%)
Constipation 4 (13.3%) 2 (6.7%)    6 (20%)
Toothache 5 (16.7%) 1 (3.3%)    6 (20%)
Fever 5 (16.7%)     5 (16.7%)
Abdominal pain 3 (10%) 1 (3.3%) 1 (3.3%)   5 (16.7%)
Thyroid-stimulating hormone increased 3 (10%) 1 (3.3%)    4 (13.3%)
Hypertriglyceridemia 1 (3.3%)   1 (3.3%) 2 (6.7%) 4 (13.3%)
Dizziness 4 (13.3%)     4 (13.3%)
Proteinuria 2 (6.7%) 1 (3.3%)    3 (10%)
Hypokalemia 2 (6.7%)    1 (3.3%) 3 (10%)
Hyponatremia 1 (3.3%) 1 (3.3%) 1 (3.3%)   3 (10%)
Cough 2 (6.7%) 1 (3.3%)    3 (10%)
Upper respiratory infection 3 (10%)     3 (10%)
Weight loss 1 (3.3%) 2 (6.7%)    3 (10%)
Headache 3 (10%)     3 (10%)